CO5170408A1 - Alfa - amino - beta - sulfonil compuestos de acido hidroxamico - Google Patents

Alfa - amino - beta - sulfonil compuestos de acido hidroxamico

Info

Publication number
CO5170408A1
CO5170408A1 CO00037327A CO00037327A CO5170408A1 CO 5170408 A1 CO5170408 A1 CO 5170408A1 CO 00037327 A CO00037327 A CO 00037327A CO 00037327 A CO00037327 A CO 00037327A CO 5170408 A1 CO5170408 A1 CO 5170408A1
Authority
CO
Colombia
Prior art keywords
hydrocarbyl
methyl
sulfonil
alfa
beta
Prior art date
Application number
CO00037327A
Other languages
English (en)
Inventor
Thomas E Barta
Daniel P Becker
Louis J Bedell
Gary A Decrescenzo
John N Freskos
Daniel P Getman
Robert M Heintz
Susan L Hockerman
H Li Madeline
V Mischke Brent
Clara I Villamil
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of CO5170408A1 publication Critical patent/CO5170408A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto que corresponde a la fórmula A, o a una sal farmacéuticamente aceptable de la misma.<EMI FILE="00037327_1" ID="1" IMF=JPEG >en dondeR2 se selecciona del grupo que consta de un radical hidrógeno, C1-C4 hidrocarbilo, hidroxi-C1-C4 hidrocarbilo, C1-C4 hidrocarbiloxi, halo-C1-C4 hidrocarbilo, C1-C4 hidrocarbiloximetilo, arilo, arilo C1-C4 hidrocarbilo, aminometilo, (N-C1-C3 hidrocarbilo)(H)metilo, (N(C1-C3-hidrocarbilo) (C1-C3-hidrocarbilo)-metilo, (N-morfolino)metilo, (N-pirrolidino)metilo, y un grupo (N-tiomorfolino)metilo.
CO00037327A 1999-05-20 2000-05-22 Alfa - amino - beta - sulfonil compuestos de acido hidroxamico CO5170408A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13499699P 1999-05-20 1999-05-20

Publications (1)

Publication Number Publication Date
CO5170408A1 true CO5170408A1 (es) 2002-06-27

Family

ID=22466022

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00037327A CO5170408A1 (es) 1999-05-20 2000-05-22 Alfa - amino - beta - sulfonil compuestos de acido hidroxamico

Country Status (16)

Country Link
US (1) US6583299B1 (es)
EP (1) EP1178959A1 (es)
JP (1) JP2003500389A (es)
KR (1) KR20020003881A (es)
CN (1) CN1373751A (es)
AR (1) AR035318A1 (es)
AU (1) AU776171C (es)
BR (1) BR0010810A (es)
CA (1) CA2373577A1 (es)
CO (1) CO5170408A1 (es)
MX (1) MXPA01011865A (es)
NZ (1) NZ515307A (es)
PE (1) PE20010408A1 (es)
UY (1) UY26158A1 (es)
WO (1) WO2000071514A1 (es)
ZA (1) ZA200109228B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055112A1 (en) * 2000-01-27 2001-08-02 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
CA2471814C (en) * 2001-12-27 2011-03-15 Sumitomo Pharmaceuticals Co., Ltd. Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
CA2682174C (en) * 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
KR102410199B1 (ko) * 2016-04-18 2022-06-17 프라운호퍼-게젤샤프트 츄어 푀르더룽 데어 안게반텐 포르슝에.파우. 새로운 메프린 알파 및 베타 저해제
CN113194954A (zh) 2018-10-04 2021-07-30 国家医疗保健研究所 用于治疗角皮病的egfr抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
JPS62221675A (ja) * 1986-03-19 1987-09-29 Mitsubishi Chem Ind Ltd β−テトラゾ−ル置換アラニン誘導体
JPH06510023A (ja) * 1991-04-18 1994-11-10 ユニバーシティ　オブ　ジョージア　リサーチ　ファウンデーション，インコーポレイテッド キヌレニナーゼの阻害剤
US5525629A (en) 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
US5376664A (en) 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
GB9307956D0 (en) 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
KR100355247B1 (ko) 1993-11-04 2003-01-24 더 리포좀 컴퍼니, 인코퍼레이티드 다층라멜라리포좀성아라키돈산대사물질
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
WO1996011209A1 (en) 1994-10-05 1996-04-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
DK0874830T3 (da) 1995-12-08 2003-04-22 Agouron Pharma Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
EP0871439B1 (en) 1996-01-02 2004-03-31 Aventis Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
KR20000022532A (ko) * 1996-06-27 2000-04-25 오노 야꾸힝 고교 가부시키가이샤 아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물
CN1230884A (zh) * 1996-07-22 1999-10-06 孟山都公司 硫羟砜金属蛋白酶抑制剂
ATE320249T1 (de) * 1997-07-08 2006-04-15 Ono Pharmaceutical Co Aminosäurederivate

Also Published As

Publication number Publication date
ZA200109228B (en) 2002-11-15
MXPA01011865A (es) 2002-06-04
JP2003500389A (ja) 2003-01-07
AU4973500A (en) 2000-12-12
PE20010408A1 (es) 2001-04-05
BR0010810A (pt) 2002-02-19
AU776171C (en) 2005-05-12
US6583299B1 (en) 2003-06-24
AR035318A1 (es) 2004-05-12
CA2373577A1 (en) 2000-11-30
WO2000071514A8 (en) 2001-02-22
CN1373751A (zh) 2002-10-09
EP1178959A1 (en) 2002-02-13
UY26158A1 (es) 2000-12-29
NZ515307A (en) 2004-08-27
AU776171B2 (en) 2004-09-02
KR20020003881A (ko) 2002-01-15
WO2000071514A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
CO5280060A1 (es) Aminoacidos biciclicos como agentes farmaceuticos
AR031828A2 (es) Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia
EP2289521A3 (en) Compositions and methods for use in tergeting vascular destruction
CO5280070A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular
BG108806A (en) IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF
ATE306261T1 (de) Antithrombosemittel
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
CO5261539A1 (es) Compuestos farmaceuticamente activos
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
NZ337298A (en) N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
DE60231555D1 (de) Verbesserte synthese von polyanhydriden
CO5200791A1 (es) Acidos 3-propil gamma-aminobutiricos mono- y disustituidos
FR2456733A1 (fr) Nouveaux acides 2-(mercapto-1-oxo(alkyl inferieur))-1,2,3,4-tetrahydroisoquinoleine-3-carboxyliques, utiles notamment comme inhibiteurs de l&#39;enzyme de conversion de l&#39;angiotensine i
CO5170408A1 (es) Alfa - amino - beta - sulfonil compuestos de acido hidroxamico
CO5180605A1 (es) Compuestos de indol
DE3586935D1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
EP0233686A3 (en) Bis phenyl ethanol amines and bis phenyoxypropanolamines having a beta-agonist activity
EP0339671A3 (en) Derivative of caffeic acid and pharmaceutical composition containing the same
JP2006518765A5 (es)
CO5140099A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
CO5180620A1 (es) Proceso para la produccion de compuestos farmaceuticamente activos, particularmente derivados de acido quinolincarboxilico con actividad bacteriana
CO5261576A1 (es) Compuestos
CO5160328A1 (es) Derivados de etan sulfonil-piperidina
EP0251380A3 (en) 2- (5-phenyl-2-furanyl) imidazoles useful as cardiotonic agents

Legal Events

Date Code Title Description
FC Application refused